Amgen will close its Onyx facility in South San Francisco in December
US biotech Amgen plans to shutter the south San Francisco, US facility of Onyx Pharmaceuticals, the oncology specialist that it acquired in September 2013. About 750 employees work at the site and roughly 300 will be laid off as part of the reorganisation, which will take effect in December. A further 250 of Onyx’s sales and medical field staff will transfer to Amgen. The fate of the rest of Onyx’s staff remains to be determined.
The cuts are part of Amgen’s ongoing plan to shed over 3000 staff by the end of 2015.